Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared a post on X:
“Sacituzumab tirumutecan +pembro – 65% risk of PD vs pembro alone in PDL1>1% mNSCLC in interim analys including Sq!
Crowded space of ADC antiTROP2 in 1st line combined with IO Geographical representation of the trial (only in China) may limit regulatory approval by FDA?”
Other articles featuring Jordi Remon on OncoDaily.
